Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181.


3574^ Background: Pmab, a fully human monoclonal antibody targeting EGFR, has demonstrated activity in combination with FOLFIRI for second-line treatment of mCRC (study 181). Here, we describe the results of a prespecified subgroup analysis of study 181 to evaluate the efficacy of pmab plus FOLFIRI vs FOLFIRI alone in pts who received prior bev. METHODS… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.